Search

Your search keyword '"Zulaica, M"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Zulaica, M" Remove constraint Author: "Zulaica, M"
73 results on '"Zulaica, M"'

Search Results

1. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (Nature Communications, (2021), 12, 1, (3417), 10.1038/s41467-021-22491-8)

2. Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia

3. New insights into the genetic etiology of Alzheimer's disease and related dementias

4. Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales

5. New insights into the genetic etiology of Alzheimer's disease and related dementias

6. Fragmentação das novas estruturas do ecossistema no periurbano, Córdoba, Argentina

7. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

8. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

9. Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort

10. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

11. Disease-related cortical thinning in presymptomatic granulin mutation carriers

12. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

13. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

14. Phenotypic correlations in a large single‐center cohort of patients with BSCL2 nerve disorders: a clinical, neurophysiological and muscle magnetic resonance imaging study

15. Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease

16. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019)

17. Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia

18. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study

19. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study

20. Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort

21. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study

22. Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort

26. Identification and characterisation of ATP2A1 variants through whole exome sequencing

27. Los límites al crecimiento, el cambio climático y la innovación

29. Metabolic Alterations in Plasma from Patients with Familial and Idiopathic Parkinson's Disease

30. Clinical and imaging spectrum of non-congenital dominant ACTN2 myopathy.

31. Altered tubulin detyrosination due to SVBP malfunction induces cytokinesis failure and senescence, underlying a complex hereditary spastic paraplegia.

32. Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis.

33. Expanding the phenotypic spectrum of TRAPPC11- related muscular dystrophy: 25 Roma individuals carrying a founder variant.

34. Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

35. Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system follow-up study.

36. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.

37. Senescence plays a role in myotonic dystrophy type 1.

38. White matter integrity changes and neurocognitive functioning in adult-late onset DM1: a follow-up DTI study.

39. Description of Two Families with New Mutations in Familial Cerebral Cavernous Malformations Genes.

40. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

41. Neurodegeneration trajectory in pediatric and adult/late DM1: A follow-up MRI study across a decade.

42. Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease.

43. Targeted Next-Generation Sequencing in a Large Cohort of Genetically Undiagnosed Patients with Neuromuscular Disorders in Spain.

44. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

45. A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis.

46. Age-related cognitive decline in myotonic dystrophy type 1: An 11-year longitudinal follow-up study.

47. A deep intronic splice variant advises reexamination of presumably dominant SPG7 Cases.

48. Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.

49. Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion".

50. Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism.

Catalog

Books, media, physical & digital resources